Directorate Change

GlaxoSmithKline PLC
15 December 2003

Issued - Monday 15 December 2003, London - LSE Announcement



                              GlaxoSmithKline PLC
               Announces Changes to the Board and its Committees



Appointment of new Executive Director

GSK announces that Dr Tadataka (Tachi) Yamada, Chairman, Pharmaceuticals
Research & Development, has been appointed an Executive Director of
GlaxoSmithKline plc with effect from 1st January 2004.

Commenting on this appointment Sir Christopher Hogg, the Chairman of GSK, said
"GlaxoSmithKline has a very strong executive team led by Dr Garnier and I am
very pleased that the Board will now benefit from the direct presence of Tachi,
who has great knowledge and experience in medicine as well as in the
pharmaceutical industry".

Appointment of a Senior Independent Non-Executive Director

Sir Ian Prosser has been appointed Senior Independent Non-Executive Director
with effect from 1st January 2004.

Commenting on this appointment Sir Christopher Hogg said, "Sir Ian is a highly
experienced senior industrialist. I look forward to working with him in his new
role as Senior Independent Non-Executive Director."

Board Committees

After careful consideration of the new Combined Code on Corporate Governance,
the Board has decided to make the following changes to the membership of its
Committees each with effect from 1st January 2004, unless otherwise stated:

Audit Committee

Sir Christopher Hogg has resigned as a member of the Audit Committee and Sir
Robert Wilson has been appointed a member of the Committee in his stead.

Remuneration Committee

Mr John McArthur, interim Chairman of the Remuneration Committee, has decided to
retire from the Board at the Company's AGM on 17th May 2004. Sir Robert Wilson
has been appointed a member of the Remuneration Committee with effect from 1st
January 2004 and will become Chairman of the Committee on Mr McArthur's
departure from the Board. Mr H. Lawrence Culp, Jr. has also been appointed a
member of the Remuneration Committee with effect from 1st January 2004. Dr
Michele Barzach and Ambassador Donald McHenry have resigned as members of the
Remuneration Committee with effect from 1st January 2004.

Nominations Committee

Sir Ian Prosser has decided to stand down as Chairman of the Committee, but will
remain a member of the Committee. Sir Christopher Hogg will chair the
Nominations Committee in his stead. Ambassador Donald McHenry has resigned as a
member of the Committee.

Biographical details of Dr Tachi Yamada are given below together with a table
showing the new membership of the Board committees mentioned above.

S M Bicknell

Company Secretary

15th December 2003



                            ________________________





Biographical Details



Dr Tachi Yamada

Age 58. Dr Tadataka (Tachi) Yamada is Chairman, Research and Development of
GlaxoSmithKline and a member of GSK's Corporate Executive Team. Dr. Yamada
joined SmithKline Beecham as a non-executive Member of the Board of Directors in
February 1994. Subsequently, he accepted a full-time position at SmithKline
Beecham as President of their Healthcare Services Division which consisted of
Diversified Pharmaceutical Services (pharmaceutical benefit management company),
SmithKline Beecham Clinical Laboratories, Health Management Services (disease
management group) and Diversified Prescription Delivery (mail order prescription
company). In February 1999, he was named Chairman, Research and Development,
SmithKline Beecham Pharmaceuticals and in January 2001 he assumed his current
position. Prior to joining SmithKline Beecham he was Chairman of the Department
of Internal Medicine at the University of Michigan Medical School and
Physician-in-Chief of the University of Michigan Medical Center.

Dr. Yamada graduated from Stanford University with a BA in history and obtained
his M.D. from New York University School of Medicine. He is a gastroenterologist
who has focused his research on the molecular biology of hormone receptors and
is the editor of The Textbook of Gastroenterology. The studies undertaken by Dr.
Yamada and his collaborators led to basic discoveries in the post-translational
processing and biological activation of peptide hormones, the structure and
function of receptors for hormones regulating gastric acid secretion, and the
regulation of genes involved in the acid secretory process. In recognition of
his contributions to medicine he has been elected to membership in the Institute
of Medicine of the National Academy of Sciences (US) and the Academy of Medical
Sciences (UK). He has been the recipient of numerous awards including the
Distinguished Achievement Award in Gastrointestinal Physiology from the American
Physiological Society, the Friedenwald Medal from the American
Gastroenterological Association, the Distinguished Faculty Achievement Award
from the University of Michigan and the Distinguished Medical Scientist Award
from the Medical College of Virginia.

Dr. Yamada is a Fellow of the Imperial College of Medicine, a Master of the
American College of Physicians, Vice-President of the Association of American
Physicians and a Past-President of the American Gastroenterological Association.
He has also been a Member of the Board of Directors of the American Board of
Internal Medicine and the National Board of Medical Examiners (US). Dr. Yamada
is a member of the Board of Directors of diaDexus and is a Trustee of the
Rockefeller Brothers Fund.















Board Committee Membership

with effect from 1st January 2004.




  Board Committee             Committee Chairman       Members         

  Audit                       Dr Ronaldo Schmitz       Sir Peter Job          
                                                       Sir Ian Prosser        
                                                       Sir Robert Wilson      

  Remuneration                John McArthur*           Mr H Lawrence Culp     
                              (to be succeeded by      Jnr.                   
                              Sir Robert Wilson from   Mr Crispin Davis       
                              17th May 2004)           Sir Peter Job          
                                                       Sir Robert Wilson      

  Nominations                 Sir Christopher Hogg     Mr John McArthur*      
                                                       Sir Ian Prosser        

  Corporate Responsibility    Ambassador Donald        Sir Christopher Hogg   
                              McHenry                  Dr Michele Barzach     
                                                       Dr Lucy Shapiro       

* Retires from the Board with effect from 17th May 2004.







GSK Enquiries:
UK Media enquiries:                                    Martin Sutton            [phone]
                                                       David Mawdsley           [phone]
                                                       Chris Hunter-Ward        [phone]

US Media enquiries:                                    Nancy Pekarek            [phone]
                                                       Mary Anne Rhyne          [phone]
                                                       Patricia Seif            [phone]

European Analyst/Investor enquiries:                   Duncan Learmouth         [phone]
                                                       Anita Kidgell            [phone]
                                                       Philip Thomson           [phone]

US Analyst/ Investor enquiries:                        Frank Murdolo            [phone]
                                                       Tom Curry                [phone]




                      This information is provided by RNS
            The company news service from the London Stock Exchange